Cannabis is now legal in 40 of 50 U.S. states for medical use, with recreational use legalized in 24 states. This has created a market for marijuana edibles, making gummies, chocolates and beverages more readily available to consumers, including minors. Reports of cannabis poisoning among children soared from 930 in 2009 to more than 22,000 in 2024 – and more than 75 percent of all cannabis poisonings involved children and teens in 2024, according to America's Poison Centers. （来源：CGTN） 随着大麻合法化与商业化席卷美国，大麻产品的 ...

Industry Overview - Cannabis stocks, including Canopy Growth and Aurora Cannabis, have seen a decline over the past five years despite initial popularity [1] - Recent regulatory changes, specifically President Trump's executive order rescheduling cannabis from Schedule 1 to Schedule 3, may provide new opportunities for the industry [3][4] Regulatory Changes - Cannabis is now classified as a Schedule 3 drug, indicating accepted medical benefits and lower potential for abuse compared to Schedule 1 and 2 substances [4] - This change could facilitate easier access to banking services and allow cannabis companies to deduct normal business expenses, potentially leading to increased revenue and profits [6] Company-Specific Insights - Canopy Growth has a market cap of $407 million, with a current price of $1.19 and a gross margin of 18.74% [5][6] - Aurora Cannabis has a market cap of $255 million, with a current price of $4.49 and a gross margin of -86.45% [8][9] - Despite the potential market size in the U.S., both companies face significant challenges, including federal illegality and competition [7][10] Market Challenges - Cannabis remains illegal at the federal level in the U.S., complicating interstate commerce for growers [7] - Aurora Cannabis lacks a retail or distribution presence in the U.S., which may hinder its ability to capitalize on market opportunities [7][9] - Canopy Growth, while having a subsidiary in the U.S., still faces similar federal and competitive challenges [10]

Core Insights - President Trump signed an executive order on December 18, 2025, to expedite the reclassification of marijuana, potentially making it a Schedule III drug, which would facilitate research and access for Medicare and Medicaid recipients [1][3] - The reclassification could lead to increased investment opportunities in the cannabis industry, which has experienced volatility [1][4] Industry Trends - Cannabis use among Americans aged 65 and older has significantly increased, rising from 4.8% in 2021 to 7% in 2023, marking a 46% increase [2] - The demand for cannabis is growing among seniors, particularly those with chronic diseases, indicating a shift in consumer demographics [6] Regulatory Environment - Marijuana is currently classified as a Schedule I substance, alongside drugs like heroin and LSD, but the executive order aims to change this classification to Schedule III, which includes drugs with recognized medical uses [3] - There is a complex legal landscape across states regarding marijuana use, with support for legalization rising from 36% in 2005 to 70% in 2023, reflecting changing consumer sentiment [5]

【文/观察者网 林琛力】在大麻行业进行了密集的游说活动后，当地时间12月18日，美国总统特朗普签 署行政令，推动大麻的"重新分类"进程，将大麻从与海洛因并列的一级管制药物，放宽为与部分常见处 方止痛药相同的三级管制药物。 据美国有线电视新闻网（CNN）报道，特朗普当日在白宫表示："这项重新分类令将大大降低大麻相关 医疗研究的开展难度，助力我们探索大麻的益处、潜在危害以及未来相关疗法。这必将产生极其积极的 影响。" 报道指出，尽管美国已有多个州实现大麻合法化，但特朗普此次签署的行政令并未在联邦层面将大麻合 法化，也不涉及娱乐用大麻相关规定，同时未对刑事司法相关条款作出调整。 《华盛顿邮报》此前报道称，民主党人和共和党人都对大麻重新分类表现出兴趣，一些政客认为大麻具 有潜在医疗价值，并且这种广泛使用的"药物"在政治上也颇受青睐。 今年以来，美国大麻行业展开了大规模游说活动，以推动特朗普采取行动放宽对大麻的管制，该行政令 也获得了大麻行业的热烈欢迎。特朗普当日提到："从未有哪件事像此次大麻重新分类一样，让我收到 如此多的相关诉求。" CNN4月曾报道，大麻行业支持的"美国权利与改革政治行动委员会"，特意在特朗普常看 ...

President Donald Trump signed an executive order on Thursday directing federal agencies to reclassify marijuana from Schedule I to Schedule III. The move sent US cannabis stocks sharply higher on expe... ...

Tilray stock price popped by nearly 30% on Tuesday as Donald Trump prepared to sign an executive order that would reschedule cannabis into a lower drug classification. It jumped to a high of $14.40, u... ...

Core Viewpoint - The U.S. government is considering reclassifying marijuana as a "lower-risk drug," which could significantly benefit the multi-billion dollar cannabis industry by easing research restrictions [1][3]. Group 1: Government Actions and Implications - President Trump indicated that the government is contemplating the reclassification of marijuana to facilitate research, which has been hindered under its current classification as a Schedule I drug [3]. - The reclassification would not legalize marijuana or decriminalize its use but would lower research barriers and enhance the legal operating environment for businesses in the cannabis sector [4]. - The potential shift in regulation aligns with a broader trend of states legalizing medical and recreational marijuana, reflecting changing societal attitudes towards cannabis [5]. Group 2: Industry Impact and Lobbying - The cannabis industry has seen significant lobbying efforts, with over $22.4 million spent on political lobbying related to cannabis products from 2018 to 2022 [5]. - The push for legalization and reclassification is closely tied to financial interests and political lobbying, indicating a strong influence of interest groups in shaping cannabis policy [5]. - Despite the potential benefits of reclassification, concerns remain regarding the health impacts of marijuana use, including addiction and mental health issues [4].

Core Insights - Tilray's stock, along with shares of other cannabis companies, experienced a significant increase following reports suggesting that President Trump may consider reclassifying marijuana as a less dangerous drug [1] Group 1: Market Reaction - The stock prices of Tilray and other cannabis firms soared, indicating a positive market sentiment driven by potential regulatory changes [1] - Investors are optimistic about the implications of reclassification on the cannabis industry, which could lead to increased market opportunities [1] Group 2: Regulatory Environment - The potential move by President Trump to reclassify marijuana could signify a shift in the regulatory landscape for cannabis, impacting both current and future investments in the sector [1] - Reclassification may reduce legal barriers and enhance the legitimacy of cannabis products, fostering growth within the industry [1]

【环球网报道 记者 张倩】据美国《华盛顿邮报》和《福布斯》杂志网站11日报道，知情人士透露，美国政府预计将推动联邦层面大幅 放宽对大麻的管制，将大麻及其衍生物的监管力度降至与部分常见处方止痛药及其他药物相同的水平。 《华盛顿邮报》援引知情人士消息称，美国总统特朗普10日在白宫椭圆形办公室与美国共和党籍众议院议长迈克·约翰逊通话时讨论了 这一计划。卫生与公共服务部长小罗伯特·肯尼迪、医疗保险和医疗补助服务中心主任穆罕默德·奥兹以及大麻相关行业高管也参与了通 话。知情人士称，特朗普预计将通过即将签署的行政令，要求联邦机构重新对大麻进行分类，从而放宽其获取限制。 报道称，知情人士同时表示，约翰逊对此持怀疑态度，他列举多项研究及数据反对重新对大麻进行分类。特朗普随后将电话转交给围 坐在他办公桌旁的行业高管们，由他们反驳约翰逊的论点。 然而，随着医用大麻以及非医用大麻在美国多州多地陆续放开，在联邦层面推进大麻合法化或去刑事犯罪化的运动悄然兴起。近来， 美国大麻合法化成蔓延之势，与利益集团利用金钱政治进行钱权交易密不可分。据美国"公开的秘密"网站统计数据显示，从2018年到 2022年，与大麻产品相关的美国企业和行业协会 ...

The company opened the doors of a new dispensary, while lawmakers in Congress submitted a new pot reform resolution.Marijuana company Curaleaf (CURLF +9.02%) is expanding its presence in a potentially massive market, a move that resonated with investors on Thursday. That, plus a new weed reform resolution filed in the U.S. Congress, helped push the multi-state operator's (MSO) stock price up by 9% that trading session. Making hay while the sun shinesAfter market close Wednesday, Curaleaf announced it had op ...